Sensorion a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, announced the appointment of Fred Chereau as Chief Executive Officer (CEO), effective June 1, 2026.
Fred brings more than 30 years of leadership and operational experience across the biotechnology, pharmaceutical, and medical device industries, combining deep expertise in rare disease drug development and regenerative medicine with a strong track record of building scalable businesses and accelerating growth.
“I am very pleased to welcome Fred, whose appointment represents a significant step forward for Sensorion and comes at a time of strong momentum across our pipeline. Fred brings an exceptional combination of rare disease expertise, deep familiarity with the gene therapy space, and a track record of high-value business development that will play a key role in accelerating the Company’s programs through their next critical phase. His leadership and business acumen are precisely what Sensorion needs as we approach pivotal milestones, and I look forward to working closely with him to deliver on the Company’s clinical and strategic ambitions,” commented Amit Munshi, Chairman of the Board of Sensorion.
Also Read: Perceptive Discovery Announces Strategic Partnership with MH3D and Launch of α-Sight™ to Advance Alpha Radiopharmaceutical Imaging
Before joining Sensorion, Fred served as Senior Vice President, Strategy and Business Development at Alexion – AstraZeneca Rare Disease, following his tenure as President and CEO of LogicBio Therapeutics, a genomic medicine company focused on rare diseases, acquired by Alexion in 2022. Prior to LogicBio, he served as President and COO of aTyr Pharma. Earlier, he led Pervasis Therapeutics as President and CEO, guiding the company to its acquisition by Shire Pharmaceuticals and subsequently shaping the hereditary angioedema franchise. He began his career in biotechnology at Genzyme, where a decade of increasing responsibility culminated as Vice President and General Manager of the Cardiovascular Business Unit. He currently serves on the Board of Directors of Coave Therapeutics. Mr. Chereau holds a B.S. in Physics from Paris University, an M.S. from ESC La Rochelle, and an MBA from INSEAD.
“I am thrilled to join Sensorion at such a defining moment for the field of hearing loss,” said Fred Chereau. “Sensorion has built something rare: a focused gene therapy platform with compelling science, a clear clinical path with SENS-601 as the first gene therapy for the most common form of genetic hearing loss, and the trust of leading academic institutions, regulatory agencies, and top-tier investors. My goal is to build on this strong foundation, deepening our partnerships, advancing our programs with urgency, and ultimately delivering transformative therapies to patients and families living with hearing disorders who have waited far too long for solutions.”
Mr. Munshi, who has served as Interim Chief Executive Officer since February 2026, will continue as Chairman of the Board of Directors. The Board extends its appreciation to Mr. Munshi for his leadership during the transition period. The Company also announced that Géraldine Honnet, M.D., Chief Medical Officer since February 2020, is stepping down from her role to join a privately held biotechnology company. During her tenure, Sensorion advanced from a preclinical-stage company to an active clinical-stage gene therapy organization, initiating the Audiogene Phase 1/2 trial and advancing SENS-601 toward first-in-human development. The Board and the entire Sensorion team extend gratitude to Dr. Honnet for her important contributions to the Company through the years and wish her well in her new position.
SOURCE: Businesswire
